29 results about "Vancomycin" patented technology

The application discloses a material for preventing tissue adhesion and hemostasis and a preparation method thereof, and relates to the technical field of medical biomaterials.The carboxymethyl cellulose, chitosan and vancomycin / ceftazidime are synergistically matched, so that the three functions of hemostasis, adhesion prevention and antibiosis are integrated;meanwhile, the water absorption and gelation of the carboxymethyl cellulose and the blood coagulation activation of the chitosan can jointly strengthen the hemostasis effect; the tissue barrier function of the chitosan and the gel isolation of the carboxymethyl cellulose can jointly improve the adhesion prevention performance; the broad-spectrum antibiosis of the vancomycin and the ceftazidime can respond to the infection risk in different surgical scenes; the material preparation process is simple, the dosage form can be adjusted according to different surgical scenes, the material has good biocompatibility and can be completely degraded, the problem that the existing medical materials have single function and are difficult to meet the needs of complex surgical wounds is solved, and the material has significant clinical application value.

The application discloses a food-borne pathogenic bacteria detection method based on composite nanomaterials and belongs to the technical field of food safety detection. The method is characterized by the following steps: synthesizing cerium-based nanomaterial DPA-Ce-GMP with enzyme-like activity based on Ce(CH3COO)3, guanosine-5'-monophosphate disodium (GMP) and 2,6-pyridine dicarboxylic acid (DPA); taking Prussian blue as a carrier; using vancomycin to identify gram-positive bacteria; and constructing a composite nanomaterial PB@DPA-Ce-GMP@Van with targeting and oxidase characteristics, namely PCV. The PCV can be precisely adsorbed on the surface of gram-positive bacteria to form a PCV / gram-positive bacteria composite. The residual PCV in the supernatant after centrifugation can quench the fluorescence of scopolamine (SC) and increase the fluorescence intensity of fluorescent red dye (AR) at the same time. The fluorescence intensity ratio (SC / AR) is used as a detection signal output. The application realizes a composite nanometer platform for rapid detection of bacteria, has high sensitivity and strong anti-interference ability, and has a detection range of 10 1 ~ 10 7 CFU / mL and a detection limit of 5 CFU / mL.

The invention relates to the technical field of biology, in particular to a broad-spectrum bacteriophage lyase mutant, an extraction and purification reagent and a kit. The invention provides a broad-spectrum bacteriophage lyase mutant, an extraction and purification reagent and a kit. A broad-spectrum bacteriophage lyase mutant nucleic acid release liquid containing protein with an amino acid sequence as shown in SEQ ID NO: 1 is adopted; the compound can efficiently act on two important clinical drug-resistant bacteria, namely methicillin-resistant staphylococcus aureus MRSA and vancomycin-resistant enterococcus VRE, at the same time. Through unique molecular design and preparation process optimization, the lyase shows excellent synchronous wall breaking capacity, cell wall destruction can be completed in an extremely short time, and the nucleic acid release efficiency is remarkably superior to that of a traditional method.

The application discloses a kind of smelly danchang dots and preparation method and application, belong to medical technical field.The preparation method of smelly danchang dot includes: smelly danchang fine powder is dispersed in distilled water, and is stirred pyrolysis on heating table;Pyrolysis product is diluted with distilled water, and supernatant is obtained by centrifugation, filter membrane filtration, dialysis, freeze-drying, to obtain carbon dot.The average particle size of obtained carbon dot is 4.51±1.04nm.The smelly danchang dot prepared in the application shows strong inhibitory activity to a variety of gram-positive bacteria (such as listeria, methicillin-resistant staphylococcus aureus MRSA) and fungi (such as Candida albicans), especially to clinically tricky drug-resistant strains, such as vancomycin-resistant enterococci (VRE) and MRSA effective, can be applied to the preparation of antibacterial drugs, antibacterial dressing, disinfectant or preservative, with the advantages of wide raw material source, simple preparation method, low cost, environment-friendly and the like.

This invention discloses the application of the bacterial fission protein FtsZ inhibitor DB1 in the preparation of drugs against drug-resistant bacteria, belonging to the field of drug development technology. The inhibitor provided by this invention is compound DB1, named 3-(2,8-dibromo-10,11-dihydro-5H-dibenzo[b,f]azapheno-5-yl)-N,N-dimethylpropylamine hydrochloride, with the molecular formula C2. 19 H 24 Br2ClN2. This compound, DB1, exhibits significant inhibitory effects against various drug-resistant bacteria, particularly vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus (MRSA), and can significantly improve the susceptibility of methicillin to MRSA. The discovery of compound DB1 provides new ideas and technical support for the preparation of drugs against drug-resistant bacteria.

The invention relates to a double-probe detection kit for detecting staphylococcus aureus in meat products and a preparation method of the double-probe detection kit, and belongs to the technical field of food safety. The double-probe detection kit is composed of a magnetic capture probe reagent and a double-signal nano-enzyme probe reagent which are independently packaged and have the same volume; the magnetic capture probe reagent is a vancomycin modified reticular magnetic bead and is used for specifically binding staphylococcus aureus in a meat product detection sample and carrying out separation and enrichment treatment; the double-signal nano-enzyme probe reagent is a blue fluorescent carbon dot modified by a nucleic acid aptamer and is used for specifically combining the staphylococcus aureus subjected to separation and enrichment treatment and generating a staphylococcus aureus concentration dependent colorimetric signal and a fluorescent signal. According to the invention, mutual verification is carried out between dual-mode signals, so that the accuracy of a detection result is improved; according to the method, the detection time is within 1.5 h, the detection time is short, the detection sensitivity is high, and the method has good specificity for common type strains.

The invention discloses a betulinic acid derivative as well as a synthesis method and application thereof. According to the betulinic acid derivative, the carboxyl position of betulinic acid C-28 is subjected to structural modification, and four halogenated aniline derivatives are obtained. Wherein the derivatives b, d and e show strong activity on staphylococcus aureus, the derivatives d and e also show strong activity on vancomycin-resistant staphylococcus aureus (VRSA), and the derivative o strongly inhibits streptococcus pneumoniae. Compared with a parent skeleton, the four derivatives show significantly enhanced antibacterial efficacy. Experimental data prove that the derivatives d and e and further derivatives thereof may provide a promising strategy for resisting drug-resistant gram-positive pathogens, and the derivative d can be further developed into a novel therapeutic agent for biofilm-mediated drug-resistant infection.

The application discloses an antibody-antibiotic conjugate and application thereof, and a structural formula of the antibody-antibiotic conjugate is shown as formula (I) and is composed of a payload antibiotic, a monoclonal antibody targeting Kdo monosaccharide and an enzyme-sensitive linker; the antibody-antibiotic conjugate has strong affinity to Kdo antigen and can be combined with Staphylococcus aureus of different serotypes. Enzymatic treatment of the antibody-antibiotic conjugate can release free antibiotics to improve the bactericidal efficiency on Staphylococcus aureus; the antibody-antibiotic conjugate can effectively kill intracellular bacteria which are difficult to be affected by traditional small-molecule antibiotics through the mediation of the antibody; in the application of a Staphylococcus aureus-induced mouse pneumonia and nephritis model, the antibody-antibiotic conjugate can effectively remove bacteria in the lung and kidney, and the therapeutic effect is better than that of vancomycin. Therefore, the antibody-antibiotic conjugate has potential application in the development of Staphylococcus aureus infection drugs.

The invention belongs to the technical field of organic synthesis, and provides a honokiol phosphine salt derivative as well as a preparation method and application thereof, and a novel magnolol derivative is designed and synthesized by integrating a cationic head group and a hydrophobic chain. The compound shows potent activity (MIC = 1-4 [mu] g / mL) on a series of gram-positive bacteria, meanwhile, the hemolytic activity is extremely low (HC50 = 106.9 [mu] g / mL), and the cytotoxicity is also low (CC50 = 19.25 [mu] g / mL). In addition, the derivative also has the capabilities of rapid sterilization, low drug resistance, good plasma stability and capability of inhibiting biofilm formation and destroying mature biofilms. And compared with vancomycin, the vancomycin-containing antibacterial peptide has the advantage that the bacterial load can be obviously reduced.

The application discloses a strain of Flammulina velutipes, a fermentation liquor of the strain and application thereof, and belongs to the technical field of microorganisms.The Flammulina velutipes strain R12 is preserved in the Guangdong Provincial Microbial Culture Collection Center on August 18, 2025, the address of the preservation center is No. 59 Building, 5th Floor, Guangzhou Xianlie Middle Road 100, and the preservation number is GDMCC NO. 66855.The fermentation liquor of the Flammulina velutipes strain R12 disclosed by the application has a specific bacteriostatic effect on vancomycin moderately drug-resistant Staphylococcus aureus XN108, and provides an important candidate substance for development of a new type of anti-Staphylococcus aureus drug.

The application discloses a chromogenic differential culture medium for separating duck Riemerella anatipestifer and application thereof, and belongs to the field of microorganism detection. The application provides the chromogenic differential culture medium based on physiological and biochemical characteristics of the duck Riemerella anatipestifer, and the chromogenic differential culture medium takes polymyxin B and vancomycin as specific antibiotics and takes X-Glu as a chromogenic substrate. The experimental results show that the chromogenic differential culture medium can efficiently inhibit growth of miscellaneous bacteria, and the duck Riemerella anatipestifer colony presents a characteristic color, so that the dual functions of selective culture and rapid identification are realized; the duck Riemerella anatipestifer identification method developed based on the chromogenic differential culture medium has the advantages of good selectivity, intuitive identification, simple operation, accurate results and the like, and the application provides new materials and methods for identification of the duck Riemerella anatipestifer and diagnosis of duck Riemerella anatipestifer disease.

This invention discloses a dual-recognition electrochemical sensor, its preparation method, and its application. The sensor comprises: (1) a working electrode modified with a molecularly imprinted polymer membrane; and (2) a vancomycin-modified copper-based metal-organic framework nanoenzyme signal probe. This signal probe specifically binds to the cell wall of Gram-positive bacteria and catalyzes the oxidation of o-phenylenediamine by peroxide to generate an electrochemical signal. During detection, the target bacteria are first captured by the molecularly imprinted layer, and the signal probe binds to the bacterial cell via vancomycin, forming a "sandwich" structure. The change in current signal is detected by differential pulse voltammetry to achieve quantitative analysis. The sensor of this invention has a detection limit as low as 1.1 CFU / mL and a linear range of 4 × 10⁻⁶. 1 -4×10 8 The CFU / mL concentration exhibits good selectivity and stability in complex samples such as cerebrospinal fluid. The preparation method of this invention is simple, low-cost, and highly sensitive, and can be used for ultrasensitive detection of Listeria monocytogenes in fields such as central nervous system infections and food safety monitoring.

Bacterial infections evading the current antibiotic arsenal warrant new treatment options. The mainstay treatment for Clostridium difficile infections involves administration of the broad-spectrum antibiotic vancomycin, which also depletes the gut microbiome and its natural defenses. This leads to recurrent C. difficile infections in 20-30% of patients. Alternative treatment options are limited, triggering a perpetual cycle of relapse and recovery that may eventually lead to death. Keratinicyclin B represents a glycopeptide antibiotic chemotype with a mechanism of action that is selective for Clostridia. When combined, vancomycin (or other glycopeptide antibiotic) and keratinicyclin B interact synergistically to inhibit the growth of C. difficile at concentrations far lower than their respective minimal inhibitory concentrations. Such a combination therapy could allow for targeted colonization clearance at low antibiotic doses, thereby minimizing toxicity and reducing the likelihood of relapse.

The invention discloses laggera pterodonta carbon dots as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method of the laggera pterodonta carbon dots comprises the following steps: dispersing laggera pterodonta fine powder in distilled water, and stirring and pyrolyzing on a heating table; and diluting the pyrolysis product with distilled water, centrifuging, taking supernate, filtering with a filter membrane, dialyzing, and freeze-drying to obtain the carbon dots. The average particle size of the obtained carbon dots is 4.51 + / -1.04 nm. The laggera pterodonta carbon dots prepared by the invention show strong inhibitory activity on various gram-positive bacteria (such as Listeria monocytogenes and methicillin-resistant staphylococcus aureus MRSA) and fungi (such as Candida albicans), and are particularly effective on clinically-difficult drug-resistant strains, such as vancomycin-resistant enterococcus (VRE) and MRSA; the compound can be applied to preparation of novel antibacterial drugs, antibacterial dressings, disinfectants or preservatives, and has the advantages of wide raw material sources, simple preparation method, low cost, environmental friendliness and the like.

This invention belongs to the field of drug detection technology, and relates to a platinum-iridium bimetallic nanozyme, its preparation method, and its application in immunochromatographic detection. The method includes: first, preparing a bimetallic nanozyme with a platinum core and an iridium shell; then, conjugating it with an antibody to create a colorimetric enhanced immunolabel. Based on this, a competitive immunochromatographic test strip is constructed, with the corresponding drug antigen immobilized on the T line and a quality control capture agent immobilized on the C line. During detection, the sample and label are mixed and added dropwise. If the sample does not contain the target drug, the labeled antibody binds to the antigen on the T line, resulting in color development; if the target drug is present, it competes with the T line for binding to the labeled antibody, leading to a weakening of the T line signal. A colorimetric solution is added, utilizing the catalytic activity of the nanozyme to amplify the signal, significantly improving sensitivity. This invention achieves detection limits of 0.41 ng / mL for vancomycin and 0.12 ng / mL for chlorpheniramine maleate, exhibiting advantages such as speed, high sensitivity, and ease of operation, making it suitable for therapeutic drug monitoring and trace drug residue detection.

The invention discloses a construction method and application of an Eriocheir sinensis intestinal flora deletion model, the method comprises the following steps: feeding Eriocheir sinensis with a feed mixed with mixed antibiotics for 96 hours to obtain the Eriocheir sinensis intestinal flora deletion model; the mixed antibiotic is prepared from metronidazole, neomycin and vancomycin. A plate culture method verifies that the optimized core antibiotic concentration group can enable the clearance rate of intestinal content florae to reach 95% or above and the clearance rate of fecal florae to reach 90% or above. According to the method, the intestinal flora deletion model of the eriocheir sinensis is constructed for the first time, the method has the advantages of being high in removal efficiency, good in repeatability, small in stress and the like, the flora is restorable after drug administration is stopped, and a standardized experimental tool is provided for studying the intestinal-brain axis mechanism, physiological metabolism and healthy breeding of crustacean.

The invention provides nitrate reducing bacteria C381 as well as a method and application thereof. The nitrate reducing bacteria C381 is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36842; the invention provides a novel oral cavity probiotic nitrate reducing bacteria C381, the nitrate reducing bacteria C381 has an inhibition effect on periodontal disease bacteria, and the nitrate reducing bacteria C381 is sensitive to antibiotics such as erythromycin, piperacillin, minocycline, doxycycline, cefazolin, tetracycline, amikacin, gentamicin, vancomycin and cefoperazone, and can be used for preparing oral cavity probiotics for treating periodontal disease bacteria. And the product has good survival ability in the oral cavity.

The invention discloses a biological source manganese oxide material as well as a preparation system and application thereof. The biological source manganese oxide is obtained by oxidizing Mn (II) in vitro by Mn (II) oxidase PomA. The biogenic manganese oxide has a relatively strong degradation effect on five antibiotics such as streptomycin, vancomycin, ciprofloxacin, sulfamethoxazole and oxytetracycline.

The invention provides bacillus C367 as well as a method and application thereof. The bacillus C367 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36841; the bacillus C367 is separated from the Inner Mongolia cheese; the bacillus C367 can be used for preparing medicines for treating or preventing periodontal diseases; the invention provides a novel oral cavity probiotic bacillus C367, the bacillus C367 has an inhibition effect on periodontal disease bacteria, and the bacillus C367 is sensitive to antibiotics such as minocycline, amikacin, tetracycline, erythromycin, cefoperazone, streptomycin, kanamycin, gentamicin, vancomycin and ceftriaxone, and has good survival ability in an oral cavity.

Disclosed are beneficial uses of Dendrobium polysaccharides, and compositions comprising them and vancomycin-sensitive bacteria for intestinal disorders. The present disclosure relates to a method of treating an intestinal disorders, such as an inflammatory bowel disease, comprising administering Dendrobium polysaccharide to an individual in need thereof. The present disclosure also relates to a method of treating an intestinal disease comprising administering vancomycin-sensitive bacteria to an individual in need thereof, wherein said individual has taken or is about to take Dendrobium polysaccharide.

The application discloses an oxazolidinone compound and a synthesis method and application thereof, which couples a compound with a structural formula IV and a compound with a structural formula V under the action of a catalyst to obtain a compound with a structural formula II, and then phosphorylates the compound with the structural formula II to obtain a compound with a structural formula I. 1 is methyl, ethyl, propyl or cyclopropyl, ethenyl; R 2 is F; R 3 is F, CH3, C2H5, CF3, CHF2, CH2F or cyclopropyl; X is chlorine (Cl), bromine (Br), iodine (I), substituted boric acid or substituted boric acid ester. The compound has strong bacteriostatic activity on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.

This invention relates to the field of materials for the prevention and treatment of local infections, and more particularly to a drug-loaded composite nanoparticle, its preparation method, and its application. The drug-loaded composite nanoparticles provided by this invention comprise hollow polydopamine grafted with vancomycin and a lipoic acid-quaternary ammonium salt ionic liquid loaded into the hollow polydopamine cavity. In this invention, the HPDA nanoparticles have a hollow structure, which provides ample space for the loading of drug molecules. The lipoic acid-quaternary ammonium salt ionic liquid can generate heat energy under microwave thermal effects, effectively killing bacteria. Furthermore, under microwave stimulation, the lipoic acid-quaternary ammonium salt ionic liquid, through the synergistic effect of microwave thermal effects and chemical sterilization, can not only enhance the bactericidal effect but also reduce the inflammatory response caused by bacterial infection.

The invention discloses a series of amphiphilic cnidium lactone-quaternary ammonium salt heterozygotes as well as a preparation method and antibacterial application thereof. According to the series of compounds, a natural compound cnidium lactone is taken as a lead, a hydrophilic quaternary ammonium salt fragment is introduced to a methoxy group through structure optimization, so that a series of amphiphilic cnidium lactone-quaternary ammonium salt heterozygotes are prepared, and the structural general formula of the amphiphilic cnidium lactone-quaternary ammonium salt heterozygotes is shown as a formula (I). The series of compounds have high in-vivo and in-vitro antibacterial activity on Staphylococcus aureus ATCC 29213 and clinically separated methicillin-resistant Staphylococcus aureus (MRSA), and the antibacterial activity of the compounds is equivalent to that of a clinical first-line drug vancomycin. Through structural optimization, the water solubility and antibacterial activity of the compound are enhanced, and the compound has relatively low in-vivo and in-vitro toxicity and hemolytic activity and is not easy to generate drug resistance. Therefore, the amphiphilic cnidium lactone-quaternary ammonium salt heterozygotes have the potential of being further developed into novel antibacterial drugs.

Multi-drug resistant (MDR) bacteria potentially pose a significant risk to people in the United States and all over the world; at the moment, the risk is the greatest where antibiotics are most commonly taken. The most notable MDR organisms are Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococcus faecium (VRE) and Carbapenem-resistant Pseudomonas aeruginosa. All three are associated with nosocomial infections. Embodiments of the present invention are directed to marine microorganism fractions and products for treating multi-drug resistant bacterial infections.

The application discloses application of bicyclic phloroglucinols in preparation of antibacterial drugs, and relates to the technical field of medicines.Bicyclic phloroglucinols (BPs) synthesized based on the skeleton of natural phloroglucinols have universal inhibitory activity on gram-positive bacteria, and the BPs can effectively reduce the effective concentration of common antibiotics (vancomycin, norfloxacin, meropenem, erythromycin and rifampicin) on bacteria, enhance the antibacterial effect of the antibiotics, and expand the antibacterial spectrum of the antibiotics. S. aureus The BPs involved in the application have the advantages of brand-new structure, high antibacterial activity, synergistic effect when combined with antibiotics, and the like, have great potential to be prepared into antibacterial drugs, and have high commercial potential.

The invention discloses a cow leather sustained-release gelatin material as well as a preparation method and application thereof, and belongs to the technical field of gelatin sustained-release materials. The preparation method comprises the following steps: dispersing hydroxyapatite in a mixed solvent of water and ethanol, adjusting the pH value to 8-10, adding a dopamine solution to obtain a reaction solution, carrying out a hydrothermal reaction on the reaction solution, and cooling to room temperature after the reaction is finished; the preparation method comprises the following steps: swelling cow leather gelatin in water for 2-3 hours, and heating at 30-50 DEG C for 20-30 minutes to obtain gelatin liquid; adding a tannic acid aqueous solution into a reaction solution containing hydroxyapatite, mixing and stirring for 0.5-1 hour, then slowly adding the gelatin solution in the step (2), continuously stirring and reacting for 2-3 hours after the addition is finished, and centrifuging and washing precipitates after the reaction is finished, so as to obtain the cow leather slow-release gelatin material. The cowhide sustained-release gelatin material prepared by the invention has the characteristics of high drug loading rate and slow sustained-release speed, can be used as a bone repair material for repairing bone defects after loading a drug (vancomycin), and has a good application prospect.

The application provides a use of Derazantinib, CAS No. 1234356-69-4, for preparing an anti-Gram-positive bacterial infection drug. The technical scheme of the application discloses a new medical use of Derazantinib. The technical scheme of the application discloses a new medical use of Derazantinib. Derazantinib shows better antibacterial activity on Staphylococcus aureus, can significantly inhibit the formation of a biofilm, and can penetrate a mature biofilm to effectively kill bacteria in the mature biofilm. Derazantinib shows more significant bactericidal activity than vancomycin. In addition, Derazantinib shows strong inhibitory effect on MRSA, MSSA, Enterococcus faecalis and other clinically drug-resistant bacteria.

The application discloses a lactobacillus plantarum resisting multiple drug-resistant bacteria and application thereof, and a lactobacillus plantarum 6-14 is separated from collected wild bird excrement, the bacterium has obvious inhibiting effect on multiple drug-resistant bacteria and non-drug-resistant bacteria, including inhibiting methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus faecalis, penicillin-resistant streptococcus pneumoniae, staphylococcus aureus, escherichia coli, salmonella enteritidis and salmonella typhimurium, and the application lays a foundation for developing good antibacterial probiotic preparations.

This invention belongs to the field of biomedical technology, specifically relating to compounds that target and inhibit aspartate transcarbamate and their application in Gram-positive bacterial infections. It features a simple synthesis method, enabling mass production of the active compound through easily scalable conventional chemical reactions; significantly enhanced antibacterial activity: a highly efficient bactericidal compound with activity superior to existing clinical drugs like vancomycin; effective removal of mature biofilms of MRSA and effective killing of bacteria within the mature biofilm, exhibiting significant anti-biofilm activity; and good safety: no potential risk of hemolytic reactions, low toxicity, and no carcinogenic, teratogenic, or mutagenic toxicity.